Revenue from operations in the same period rose 12% year-on-year to Rs 2,893 crore. The same stood at Rs 2,579 crore in the previous year period.
UBS sells shares worth Rs 480 crore in Concord Biotech, IIFL Securities, 2 more stocks via block deals
UBS sold holdings in Concord Biotech, Five Star Business Finance, IIFL Securities, and Marksans Pharma through block deals, totaling Rs 480 crore. The largest sale